The Top 5 Biosimilars Articles for the Week of March 23

The Center for Biosimilars® recaps the top stories for the week of March 23, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of March 23, 2020.

Number 5: Sheila Frame, US head of Marketing and Market Access and Patient Services for Sandoz, discusses her company’s growing portfolio, the pipeline of biosimilar drugs, and the need for a more robust biosimilars market in the United States.

Number 4: In guidance issued specifically in response to the COVID-19 pandemic, the FDA has advised that clinical trial protocol changes may be made but must be documented and reported as promptly as possible.

Number 3: Oncology supportive care, oncology, and immunology biosimilars make up the 3 main classes of biosimilars that have emerged on the US market. However, rates of uptake are vastly different owing to a variety of factors.

Number 2: Two new bills aimed at increasing access to biosimilars and saving billions of dollars in out-of-pocket costs have been introduced in Congress. Both have been referred to committees for further review.

Number 1: As the COVID-19 pandemic unfolded and disrupted pharmaceutical production, a panel of experts advocated for better education and legislation for biosimilars in order to improve uptake in the US and create affordable alternatives for patients.

To read all of these articles and more, visit centerforbiosimilars.com.